Score Overview
Explore the 2021 public Archive ranking →
Where Neurocrine Biosciences Inc has ranked, year by year
Showing 10 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- NBIX
2007: 99.0% · 2021: 45.1% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-28 | $ 140.44 | — |
1 Year2025-09-26 | $ 142.00 | -1.10% |
5 Years2021-09-28 | $ 95.27 | 47.41% |
10 Years2016-09-28 | $ 51.42 | 173.12% |
20 Years2006-09-28 | $ 10.87 | 12x |
30 Years1996-09-27 | $ 11.00 | 12x |
All Time1996-05-23 | $ 12.50 | 11x |
| Period | Last Price2026-09-28 | 1 Year2025-09-26 | 5 Years2021-09-28 | 10 Years2016-09-28 | 20 Years2006-09-28 | 30 Years1996-09-27 | All Time1996-05-23 |
|---|---|---|---|---|---|---|---|
| Price | $ 140.44 | $ 142.00 | $ 95.27 | $ 51.42 | $ 10.87 | $ 11.00 | $ 12.50 |
| Return | — | -1.10% | 47.41% | 173.12% | 12x | 12x | 11x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 3.37B | $ 705M | $ 389M |
| 2025 | $ 2.86B | $ 478M | $ 1.48B |
| 2024 | $ 2.35B | $ 341M | $ 1.07B |
| 2023 | $ 1.88B | $ 249M | $ 1.03B |
| 2022 | $ 1.48B | $ 154M | $ 989M |
| 2021 | $ 1.13B | $ 89M | $ 711M |
| 2020 | $ 1.04B | $ 407M | $ 801M |
| 2019 | $ 788M | $ 37M | $ 670M |
| 2018 | $ 451M | $ 21M | $ 650M |
| 2017 | $ 161M | -$ 142M | $ 515M |
| 2016 | $ 15M | -$ 141M | $ 307M |
| 2015 | $ 19M | -$ 88M | $ 379M |
| 2014 | $ 0.00 | -$ 60M | $ 193M |
| 2013 | $ 2M | -$ 46M | $ 145M |
| 2012 | $ 53M | $ 5M | $ 173M |
| 2011 | $ 77M | $ 37M | $ 129M |
| 2010 | $ 33M | -$ 7M | $ 126M |
| 2009 | $ 2M | -$ 51M | $ 53M |
| 2008 | $ 3M | -$ 88M | $ 80M |
| 2007 | $ 1M | -$ 207M | $ 179M |
| 2006 | $ 39M | -$ 107M | $ 182M |
| 2005 | $ 123M | -$ 22M | $ 273M |
| 2004 | $ 85M | -$ 45M | $ 301M |
| 2003 | $ 139M | -$ 30M | $ 453M |
| 2002 | $ 18M | -$ 94M | $ 244M |
| 2001 | $ 41M | -$ 36M | $ 319M |
| 2000 | $ 14M | -$ 28M | $ 164M |
| 1999 | $ 16M | -$ 16M | $ 91M |
| 1998 | $ 16M | -$ 20M | $ 11M |
| 1997 | $ 26M | $ 5M | $ 15M |
| IPO1996 | $ 19M | $ 5M | $ 11M |
Neurocrine Biosciences Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 1.04B to $ 2.86B and net income grew from $ 407M to $ 478M. Revenue increased in every one of those 5 years; net income in every one.
Between 2015 and 2025, revenue grew from $ 19M to $ 2.86B and net income went from -$ 88M to $ 478M. Revenue increased in every one of those 10 years; net income in 8.
Neurocrine Biosciences Inc currently holds a 20-year HDB Score of 6.4 out of 10. How the HDB Score is calculated.
Membership
Continue NBIX’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,816 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
